Phase 2 Trial of Mecbotamab Vedotin (BA3011), CAB-AXL-ADC, Alone or in Combination with Nivolumab in Patients with Non-Squamous NSCLC

BA3011 AXL NSCLC

December 4,2023





BioAtla | Overview

Important Notices & Disclaimers

This presentation (the "Presentation") by BioAtla, Inc. ("we", "us", "our", "BioAtla", or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to statements regarding business plans and prospects and whether our clinical trials will support registration; achievement of milestones; results, conduct, progress and timing of our research and development programs and clinical trials; expectations with respect to enrollment and dosing in our clinical trials, plans and expectations regarding future data updates, clinical trials, regulatory meetings and regulatory submissions; plans to form collaborations or other strategic partnerships for selected assets; the potential regulatory approval path for our product candidates; expectations about the sufficiency of our cash and cash equivalents and plans to prioritize and focus development on selected assets and indications. Words such as, but not limited to, "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "potential", "predict", "project", "should", "will", "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes, identify forward-looking statements.

These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Presentation and are subject to risks and uncertainties, including those described in the Company's filings with the SEC, including but not limited to the Company's latest Quarterly Report on Form 10-Q. Moreover, the Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for management to predict all risks, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The Company qualifies all the forward-looking statements in this Presentation by these cautionary statements. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Statements contained herein are made as of the date of this Presentation unless stated otherwise, and this Presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that the information will be updated or revisited to reflect information that subsequently becomes available or changes occurring after that date hereof.

Certain information contained in this Presentation relates to or is based on statistical and other industry and market data obtained from independent industry publications and research, surveys and studies conducted by independent third parties as well as the Company's own estimates of the prevalence of certain diseases and conditions. The market data used in this Presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. The Company's estimates of the patient population with the potential to benefit from treatment with any product candidates the Company may develop include several key assumptions based on its industry knowledge, industry publications and third-party research, which may be based on a small sample size and may fail to accurately reflect the addressable patient population. While the Company believes that its internal assumptions are reasonable, no independent source has verified such assumptions.

This Presentation may contain trademarks, trade names, or service marks belonging to other entities. The Company does not intend the use or display of other parties' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of, or by these other parties.

None of the Company or any of its directors, officers, employees, contractors, agents, consultants, advisors or other representatives makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained in this Presentation.

KOL AXL NSCLC Agenda

1.	Opening Remarks CAB Technology
2.	BA3011 AXL as a prognostic factor Clinical data
3.	Next Steps Registrational trial designs
4.	Q & A Session



BioAtla[©] is a clinical stage company focused on transforming cancer therapy with Conditionally Active Biologics (CABs)

Proprietary technology Broad applicability in solid tumors

Increases therapeutic window

Two Phase 2 CAB-ADCs, one Phase 2 CAB-CTLA-4 and one Phase 1 dual CABbispecific T-cell engager

BA3011 advancing potentially registrational trial in sarcoma (UPS)

Diversified pipeline

Clinical readouts for multiple indications / assets through 2023/2024

Advancing strategic collaboration discussions Strong cash position

\$141.3 million in cash and cash equivalents as of 09/30/23

Sufficient into 2H 2025

Focused pipeline with broad applicability of differentiated CAB assets designed to deliver near-term value

	CAB Program	Target	Indications	IND Enabling Pre-Clinical	Phase 1 Clinical	Phase 2 Clinical
CAB-ADCs	BA3011 Mecbotamab Vedotin	AXL	Undifferentiated Pleiomorphic Sarcoma (UPS) NSCLC			
CAB	BA3021 Ozuriftamab Vedotin	ROR2	Melanoma NSCLC SCCHN	_		
CAB- I/O	BA3071	CTLA-4	Multiple tumor types**			
CAB- Bispe cific TCE	BA3182	EpCAM x CD3	Adenocarcinoma** Multiple tumor types**			
CAB	Additional programs	Various	Multiple tumor types**			



Selective and targeted CAB technology widens therapeutic window,

thus has the potential to enhance clinical outcomes in multiple tumor types



BioAtla discovered that acidic pH at the cancer cell surface unveils binding sites that are shielded at normal pH of healthy cells




BioAtla invented CAB technology, creating antibodies that bind **only** to these unveiled sites on cancer cells



CAB binding region is not masked or caged and thus different from prodrugs that require irreversible enzymatic cleavage to become activated




CAB antibodies have the potential for increased efficacy with improved safety relative to traditional antibodies



Chang, H.W., Frey, G., Liu, H., Xing, C., Steinman, L, Boyle, B.J., & Short, J.M. (2021) PNAS 118(9): 1-10, Suppl. 1-19.



CAB AXL antibody binds selectively and reversibly based on the cellular microenvironment



BioAtla Overview **7**

Carl M. Gay, MD, PhD

Assistant Professor, Department of Thoracic-Head & Neck Med Onc at MD Anderson Cancer Center

Dr. Gay graduated from Johns Hopkins University in 2005 (BA, Biology) and then enrolled at New York University School of Medicine, where he obtained his PhD (2011, Cellular & Molecular Biology) and MD (2013) degrees.

He completed his residency at the University of Texas Health Science Center at Houston before joining MD Anderson Cancer Center in 2015 as a clinical fellow. In 2019, Dr. Gay was appointed Assistant Professor in the Department of Thoracic/Head & Neck Medical Oncology.


As a clinical investigator, Dr. Gay designs and oversees clinical trials for a variety of thoracic malignancies with a particular focus in small cell lung cancer. Dr. Gay's research includes identifying novel therapeutics and predictive biomarkers for patients with lung cancer including the receptor tyrosine kinase AXL.

Dr. Gay has been the recipient of the American Society of Clinical Oncology Young Investigator Award, the Cancer Research Prevention Institute of Texas Early Clinical Investigator Award, and the LUNGevity Foundation's Career Development Award.






AXL expression is associated poor prognosis in metastatic NSCLC



In a cohort of 98 patients with metastatic NSCLC, OS was significantly worse for those patients with high AXL expression by IHC

Wu et al., J Cancer Res and Clin Oncol, 2017




Lower overall survival (OS) in patients with early stage, surgically resected lung adenocarcinoma with high levels of tissue AXL

Reproduced from de Miguel-Pérez D, et al. 2019



In NSCLC, AXL and EMT are inextricably linked with therapeutic resistance



EMT and AXL expression are correlated, and both are more common in relapsed/chemorefractory NSCLC patient samples (BATTLE 2) than treatment-naïve samples (TCGA).




EMT - epithelial to mesenchymal transition

Ramkumar K, et al. Mol Canc Res, 2021

BA3011-002 Non-Small Cell Lung Cancer

Multicenter, Phase 2, open-label trial evaluating the efficacy and safety of BA3011 alone and in combination with nivolumab



*Coded by MedDRA and graded according to NCI CTCAE v5



Phase 2 BA3011-002 NSQ NSCLC: Baseline Demographics and Characteristics

BioAtla study enrolled a heavily pretreated 3L+ population

	BA3011 monotherapy (N=23)	BA3011 + nivolumab (N=17)	Total (N=40)
Age, y, mean (SD)	68.3 (8.0)	68.9 (8.2)	68.6 (8.0)
Number of prior systemic therapies, n (%)			
1	4 (17.4)	2 (11.8)	6 (15.0)
2	6 (26.1)	3 (17.6)	9 (22.5)
3	9 (39.1)	2 (11.8)	11 (27.5)
≥4	4 (17.4)	10 (58.8)	14 (35.0)
Received prior anti-PD-1/L1 treatment, n (%)			
Yes	21 (91.3)	15 (88.2)	36 (90.0)
No	2 (8.7)	2 (11.8)	4 (10.0)
EGFR mutation status, n (%)			
Wild-type	16 (69.6)	13 (76.5)	27 (67.5)
Mutant	4 (17.4)	2 (11.8)	6 (15.0)
Unknown or missing	3 (13.0)	2 (11.8)	7 (17.5)



Phase 2 BA3011 Non-Squamous NSCLC


Monotherapy 1.8 mg/kg Q2W shows encouraging efficacy signals

Data Cut Date: 30Jun23	Prior PD-1/L1 treatment EGFR wild-type (N=15)	Prior PD-1/L1 treatment (N=18)	
Best Overall Response, n (%)			
Confirmed PR	3 (20.0)	3 (16.7)	
Unconfirmed PR	2 (13.3)	2 (11.1)	
SD	7 (46.7)	10 (55.6)	
PD	2 (13.3)	2 (11.1)	
NA (early discontinuation due to AE)	1 (6.7)	1 (5.6)	
Response Rate			
n (%)	5 (33.3)	5 (27.8)	
Exact 95% Cl	11.8, 61.6	9.7, 53.5	
Disease Control Rate			
n (%)	8 (53.3)	10 (55.6)	
Exact 95% Cl	26.6, 78.7	30.8, 78.5	

- Monotherapy median Duration of Response was estimated to be 4.8 months with a range of 2.3-12.1+ months*
- Combination therapy (n=17)*:
 - Evaluable patients (majority with 4+ prior lines of therapy) received BA3011 + nivolumab
 - One patient experienced an ongoing complete response (CR), 2 patients experienced PR, and 8 patients experienced stable disease (SD)




BA3011 Monotherapy 1.8 mg/kg Q2W






BA3011 Monotherapy 1.8 mg/kg Q2W






Data Cut Date: 30Jun23

BA3011 Monotherapy 1.8 mg/kg Q2W






BA3011 Monotherapy 1.8 mg/kg Q2W





Data Cut Date: 30Jun23

Radiographic response to BA3011 monotherapy



Red circle on top indicates subcarinal mass, resolved below. Note also improvement in malignant pleural effusion.

Summary of Treatment Emergent Adverse Events (non-squamous NSCLC)

	BA3011 monotherapy (n=23)	BA3011 + nivolumab (n=17)	Total (N=40)
TEAEs with CTCAE grade 3 or 4	15 (65.2)	8 (47.1)	23 (57.5)
Related grade 3 or 4 AEs	8 (34.8)	3 (17.6)	11 (27.5)
Any serious TEAEs	9 (39.1)	5 (29.4)	14 (35.0)
Related SAEs	3 (13.0)	1 (5.9)	4 (10.0)
TEAEs leading to treatment d/c	1 (4.3)	1 (5.9)	2 (5.0)
Related AEs leading to treatment d/c	1 (4.3)	1 (5.9)	2 (5.0)
TEAEs leading to death	0	1 (5.9)	1 (2.5)
Related AEs leading to death	0	0	0



Treatment Emergent Adverse Events (Non-Squamous NSCLC)

Any grade (\geq 15% of patients) OR grade \geq 3^{*} (\geq 3% of patients) in the study population

Preferred term	TEAEs of any grade, n (%)	TEAEs of grade 3, n (%)	
Fatigue	14 (35.0)	1 (2.5)	
Diarrhea	10 (25.0)	1 (2.5)	
Constipation	9 (22.5)	0	
Decreased appetite	9 (22.5)	1 (2.5)	
Anemia	8 (20.0)	2 (5.0)	
Nausea	8 (20.0)	0	
Peripheral neuropathy	7 (17.5)	1 (2.5)	
Increased AST	7 (17.5)	3 (7.5)	
Dyspnea	6 (15.0)	2 (5.0)	
Neutropenia	6 (15.0)	2 (5.0)	
Increased ALT	5 (12.5)	3 (7.5)	

*No grade 4+ TEAEs among most frequent.



Phase 2 BA3011 NSCLC Dose Optimization

In-line with FDA Project Optimus


- 3Q4W dosing regimen
 - 3 patients have been evaluable (1 SD and 2 PD)
 - Suboptimal compliance observed and enrollment has been discontinued
- 2Q3W dosing regimen
 - 11 patients treated
 - 4 patients have been evaluable (3 SD and 1 PD) to date

Benefit-Risk profile observed to date with 1.8 mg/kg Q2W supports advancing this dose in registrational studies



BA3011 NSCLC AXL Expression in Relation to Anti-tumor Activity

Considerable anti-tumor activity among patients regardless of AXL expression level



Best %Change in Sum of Target Lesions

Anti-tumor activity seen among patients with AXL low expression level supports target agnostic development



BA3011 NSCLC Randomized Registrational Study Design

Two Potentially Registrational Paths Enabled via the FDA Type C Meeting

2nd Line +

- Open-label; control: docetaxel
- Patients with NSCLC who have been previously treated with at least one prior line of therapy for metastatic disease
- Dual primary endpoints: Progression Free Survival and Overall Survival

3rd Line +

- **Blinded**; control: chemo monotherapy
- Patients with NSCLC who have been previously treated with at least two prior lines of therapy for metastatic disease
- Primary endpoint: Overall Survival





Q & A Session

confidential